Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The price of Genmab ADR (NASDAQ: GMAB) closed at $31.24 in the last session, up 1.00% from day before closing price of $30.93. In other words, the price has increased by $1.00 from its previous closing price. On the day, 1.68 million shares were traded. GMAB stock price reached its highest trading level at $31.4065 during the session, while it also had its lowest trading level at $30.81.
Ratios:
We take a closer look at GMAB’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.64 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.41. For the most recent quarter (mrq), Quick Ratio is recorded 6.01 and its Current Ratio is at 6.03. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 17 ’25 when Klimovsky Judith V bought 1,300 shares for $51.69 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GMAB now has a Market Capitalization of 19366748160 and an Enterprise Value of -1345639168. As of this moment, Genmab’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.27, and their Forward P/E ratio for the next fiscal year is 19.77. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.33. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.36 while its Price-to-Book (P/B) ratio in mrq is 3.34. Its current Enterprise Value per Revenue stands at -0.35 whereas that against EBITDA is -0.914.
Stock Price History:
The Beta on a monthly basis for GMAB is 0.90, which has changed by 0.49782085 over the last 52 weeks, in comparison to a change of 0.13042927 over the same period for the S&P500. Over the past 52 weeks, GMAB has reached a high of $33.65, while it has fallen to a 52-week low of $17.24. The 50-Day Moving Average of the stock is 1.16%, while the 200-Day Moving Average is calculated to be 27.93%.
Shares Statistics:
According to the various share statistics, GMAB traded on average about 2.08M shares per day over the past 3-months and 1330770 shares per day over the past 10 days. A total of 615.99M shares are outstanding, with a floating share count of 615.99M. Insiders hold about 0.00% of the company’s shares, while institutions hold 10.31% stake in the company. Shares short for GMAB as of 1764288000 were 11896539 with a Short Ratio of 5.73, compared to 1761868800 on 10539384. Therefore, it implies a Short% of Shares Outstanding of 11896539 and a Short% of Float of 1.95.
Earnings Estimates
As of right now, 4.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $0.31, with high estimates of $0.31 and low estimates of $0.31.
Analysts are recommending an EPS of between $2.01 and $1.78 for the fiscal current year, implying an average EPS of $1.92. EPS for the following year is $1.51, with 5.0 analysts recommending between $2.58 and $1.01.
Revenue Estimates
According to 8 analysts,. The current quarter’s revenue is expected to be $6.58B. It ranges from a high estimate of $7.21B to a low estimate of $6.19B. As of. The current estimate, Genmab ADR’s year-ago sales were $6.44BFor the next quarter, 8 analysts are estimating revenue of $6.13B. There is a high estimate of $6.61B for the next quarter, whereas the lowest estimate is $5.34B.
A total of 17 analysts have provided revenue estimates for GMAB’s current fiscal year. The highest revenue estimate was $25.25B, while the lowest revenue estimate was $23.08B, resulting in an average revenue estimate of $23.89B. In the same quarter a year ago, actual revenue was $21.53BBased on 15 analysts’ estimates, the company’s revenue will be $27.54B in the next fiscal year. The high estimate is $29.32B and the low estimate is $25.27B.
